A Network Medicine Framework Identifies Dihydroisotanshinone I as a SKP2-Targeting Anti-Breast Cancer Agent with Potent Activity in Triple-Negative Breast Cancer

Saisai Tian; Jinyuan Lu; Chengyang Guo; Wenjing Gu; Pengli Huang; Xike Xu; Qun Wang; Weidong Zhang

doi:10.1016/j.eng.2026.07.014

Engineering ›› :202607014 DOI: 10.1016/j.eng.2026.07.014

research-article

A Network Medicine Framework Identifies Dihydroisotanshinone I as a SKP2-Targeting Anti-Breast Cancer Agent with Potent Activity in Triple-Negative Breast Cancer

Saisai Tian ^a^,^b^,^#
, Jinyuan Lu ^c^,^#
, Chengyang Guo ^a^,^#
, Wenjing Gu ^d
, Pengli Huang ^e
, Xike Xu ^a^,^*
, Qun Wang ^c^,^*
, Weidong Zhang ^a^,^c^,^d^,^f^,^g^,^*

Author information +

^a Department of Phytochemistry, School of Pharmacy, Second Military Medical University , Shanghai 200433, China

^b Key Laboratory of Molecular Pharmacology and Drug Evaluation of the Ministry of Education, Yantai University , Yantai 264005, China

^c Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine , Shanghai 201203, China

^d Pharmacy College, Fujian University of Traditional Chinese Medicine , Fuzhou 350122, China

^e Chengdu OrganoidMed Medical Laboratory , Chengdu 610041, China

^fState Key Laboratory for Quality Ensurance and Sustainable Use of Dao—di Herbs, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100193, China

^g The Research Center for Traditional Chinese Medicine & Shanghai Institute of Infectious Diseases and Biosafety & Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine , Shanghai 201203, China

^*E-mail addresses: wdzhangy@hotmail.com (W. Zhang),

xkxu@smmu.edu.cn (X. Xu),

qunwang0523@163.com (Q, Wang).

Show less

History +

PDF (8599KB)

Abstract

Cite this article

Download citation ▾

Saisai Tian, Jinyuan Lu, Chengyang Guo, Wenjing Gu, Pengli Huang, Xike Xu, Qun Wang, Weidong Zhang. A Network Medicine Framework Identifies Dihydroisotanshinone I as a SKP2-Targeting Anti-Breast Cancer Agent with Potent Activity in Triple-Negative Breast Cancer. Engineering 202607014 DOI:10.1016/j.eng.2026.07.014

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Siegel RL, Giaquinto AN, Jemal A . Cancer statistics, 2024. CA Cancer J Clin 2024; 74(1):12-49.

[2]	Derakhshan F, Reis—Filho JS . Pathogenesis of triple—negative breast cancer. Annu Rev Pathol 2022; 17(1):181-204.

[3]	Leon—Ferre RA, Goetz MP . Advances in systemic therapies for triple negative breast cancer. BMJ 2023; 381:e071674.

[4]	Bianchini G, De Angelis C, Licata L, Gianni L . Treatment landscape of triple—negative breast cancer—expanded options, evolving needs. Nat Rev Clin Oncol 2022; 19(2):91-113.

[5]	Leung EL, Xu S . Traditional Chinese medicine in cardiovascular drug discovery. Pharmacol Res 2020; 160:105168.

[6]	Wang L, Aliyari S, Sands N, Lee B, Yu A, Xia S, et al. Impacts of neutralizing antibody responses on SARS—CoV—2 evolution and its associated disease progression. Immun Inflamm 2026; 2(1):5.

[7]	Tian S, Zhang J, Yuan S, Wang Q, Lv C, Wang J, et al. Exploring pharmacological active ingredients of traditional Chinese medicine by pharmacotranscriptomic map in ITCM. Brief Bioinform 2023; 24(2):bbad027.

[8]	Ma P, Yuan L, Jia S, Zhou Z, Xu D, Huang S, et al. Lonicerae Japonicae Flos with the homology of medicine and food: a review of active ingredients, anticancer mechanisms, pharmacokinetics, quality control, toxicity and applications. Front Oncol 2024; 14:1446328.

[9]	Efferth T, Li PC, Konkimalla VS, Kaina B . From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007; 13(8):353-61.

[10]	Richard C, Matthews D, Duivenvoorden W, Yau J, Wright PS, Th’ng JP . Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids. Clin Cancer Res 2005; 11(9):3523—9.

[11]	Zhao W, Zheng XD, Tang PY, Li HM, Liu X, Zhong JJ, et al. Advances of antitumor drug discovery in traditional Chinese medicine and natural active products by using multi—active components combination. Med Res Rev 2023; 43(5):1778-808.

[12]	Zhu Y, Ouyang Z, Du H, Wang M, Wang J, Sun H, et al. New opportunities and challenges of natural products research: when target identification meets single—cell multiomics. Acta Pharm Sin B 2022; 12(11):4011—39.

[13]	Ma S, Liu J, Li W, Liu Y, Hui X, Qu P, et al. Machine learning in TCM with natural products and molecules: current status and future perspectives. Chin Med 2023; 18(1):43.

[14]	Tian S, Li Y, Xu J, Zhang L, Zhang J, Lu J, et al. COIMMR: a computational framework to reveal the contribution of herbal ingredients against human cancer via immune microenvironment and metabolic reprogramming. Brief Bioinform 2023; 24(6):bbad346.

[15]	Tian S, Liao X, Cao W, Wu X, Chen Z, Lu J, et al. GSFM: a genome—scale functional module transformation to represent drug efficacy for in silico drug discovery. Acta Pharm Sin B 2025; 15(1):133—50.

[16]	Sadybekov AV, Katritch V . Computational approaches streamlining drug discovery. Nature 2023; 616(7958):673-85.

[17]	Liu Q, Chen Z, Wang B, Pan B, Zhang Z, Shen M, et al. Leveraging network target theory for efficient prediction of drug—disease interactions: a transfer learning approach. Adv Sci 2025; 12(11):e2409130.

[18]	Tian S, Xu M, Geng X, Fang J, Xu H, Xue X, et al. Network medicine—based strategy identifies maprotiline as a repurposable drug by inhibiting PD—L1 expression via targeting SPOP in cancer. Adv Sci 2025; 12(1):e2410285.

[19]	Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt HHHW . Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci 2022; 43(2):136—50.

[20]	Ocana A, Pandiella A, Privat C, Bravo I, Luengo—Oroz M, Amir E, et al. Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomark Res 2025; 13(1):45.

[21]	Sadegh S, Skelton J, Anastasi E, Bernett J, Blumenthal DB, Galindez G, et al. Network medicine for disease module identification and drug repurposing with the NeDRex platform. Nat Commun 2021; 12(1):6848.

[22]	Misselbeck K, Parolo S, Lorenzini F, Savoca V, Leonardelli L, Bora P, et al. A network—based approach to identify deregulated pathways and drug effects in metabolic syndrome. Nat Commun 2019; 10(1):5215.

[23]	Lal JC, Mao C, Zhou Y, Gore—Panter SR, Rennison JH, Lovano BS, et al. Transcriptomics—based network medicine approach identifies metformin as a repurposable drug for atrial fibrillation. Cell Rep Med 2022; 3(10):100749.

[24]	Fang J, Zhang P, Zhou Y, Chiang CW, Tan J, Hou Y, et al. Endophenotype—based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease. Nat Aging 2021; 1(12):1175-88.

[25]	Morselli Gysi D, do Valle Í, Zitnik M, Ameli A, Gan X, Varol O, et al. Network medicine framework for identifying drug—repurposing opportunities for COVID—19. Proc Natl Acad Sci USA 2021; 118(19):e2025581118.

[26]	Han YM, Oh H, Na M, Kim BS, Oh WK, Kim BY, et al. PTP1B inhibitory effect of abietane diterpenes isolated from Salvia miltiorrhiza . Biol Pharm Bull 2005; 28(9):1795—7.

[27]	Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barabási AL, et al. Network—based approach to prediction and population—based validation of in silico drug repurposing. Nat Commun 2018; 9(1):2691.

[28]	Rolland T, Taşan M, Charloteaux B, Pevzner SJ, Zhong Q, Sahni N, et al. A proteome—scale map of the human interactome network. Cell 2014; 159(5):1212-26.

[29]	Rual JF, Venkatesan K, Hao T, Hirozane—Kishikawa T, Dricot A, Li N, et al. Towards a proteome—scale map of the human protein—protein interaction network. Nature 2005; 437(7062):1173-8.

[30]	Csabai L, Ölbei M, Budd A, Korcsmáros T, Fazekas D . SignaLink: multilayered regulatory networks. Methods Mol Biol 2018; 1819:53-73.

[31]	Luck K, Kim DK, Lambourne L, Spirohn K, Begg BE, Bian W, et al. A reference map of the human binary protein interactome. Nature 2020; 580(7803):402—8.

[32]	Huttlin EL, Bruckner RJ, Navarrete—Perea J, Cannon JR, Baltier K, Gebreab F, et al. Dual proteome—scale networks reveal cell—specific remodeling of the human interactome. Cell 2021; 184(11):3022-40.e28.

[33]	Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, et al. ChEMBL: a large—scale bioactivity database for drug discovery. Nucleic Acids Res 2012; 40(Database issue):D1100-7.

[34]	Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK . BindingDB: a web—accessible database of experimentally determined protein—ligand binding affinities. Nucleic Acids Res 2007; 35(Database issue):D198-201.

[35]	Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M . STITCH 5: augmenting protein—chemical interaction networks with tissue and affinity data. Nucleic Acids Res 2016; 44(D1):D380—4.

[36]	Yan D, Zheng G, Wang C, Chen Z, Mao T, Gao J, et al. HIT 2.0: an enhanced platform for Herbal Ingredients’ Targets. Nucleic Acids Res 2022; 50(D1):D1238—43.

[37]	Xue R, Fang Z, Zhang M, Yi Z, Wen C, Shi T . TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis. Nucleic Acids Res 2013; 41(Database issue):D1089—95.

[38]	Komatsu M, Yoshimaru T, Matsuo T, Kiyotani K, Miyoshi Y, Tanahashi T, et al. Molecular features of triple negative breast cancer cells by genome—wide gene expression profiling analysis. Int J Oncol 2013; 42(2):478-506.

[39]	Maubant S, Tesson B, Maire V, Ye M, Rigaill G, Gentien D, et al. Transcriptome analysis of Wnt3a—treated triple—negative breast cancer cells. PLoS One 2015; 10(4):e0122333.

[40]	Maire V, Némati F, Richardson M, Vincent—Salomon A, Tesson B, Rigaill G, et al. Polo—like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple—negative breast cancer. Cancer Res 2013; 73(2):813-23.

[41]	Karaayvaz M, Cristea S, Gillespie SM, Patel AP, Mylvaganam R, Luo CC, et al. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single—cell RNA—seq. Nat Commun 2018; 9(1):3588.

[42]	Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal and scalable single—cell analysis. Nat Biotechnol 2024; 42(2):293-304.

[43]	Wang JZ, Du Z, Payattakool R, Yu PS, Chen CF . A new method to measure the semantic similarity of GO terms. Bioinformatics 2007; 23(10):1274-81.

[44]	Yu G, Li F, Qin Y, Bo X, Wu Y, Wang SJB . GOSemSim: an R package for measuring semantic similarity among GO terms and gene products. Bioinformatics 2010; 26(7):976—8.

[45]	Yang J, Tian S, Zhao J, Zhang W . Exploring the mechanism of TCM formulae in the treatment of different types of coronary heart disease by network pharmacology and machining learning. Pharmacol Res 2020; 159:105034.

[46]	Chen L, Zhang YH, Zhang Z, Huang T, Cai YD . Inferring novel tumor suppressor genes with a protein—protein interaction network and network diffusion algorithms. Mol Ther Methods Clin Dev 2018; 10:57-67.

[47]	Fang H, Gough J . The ‘dnet’ approach promotes emerging research on cancer patient survival. Genome Med 2014; 6(8):64.

[48]	Cheng F, Lu W, Liu C, Fang J, Hou Y, Handy DE, et al. A genome—wide positioning systems network algorithm for in silico drug repurposing. Nat Commun 2019; 10(1):3476.

[49]	Guo WF, Zhang SW, Feng YH, Liang J, Zeng T, Chen L . Network controllability—based algorithm to target personalized driver genes for discovering combinatorial drugs of individual patients. Nucleic Acids Res 2021; 49(7):e37.

[50]	Li Y, Zhang SW, Xie MY, Zhang T . PhenoDriver: interpretable framework for studying personalized phenotype—associated driver genes in breast cancer. Brief Bioinform 2023; 24(5):bbad291.

[51]	Guney E, Menche J, Vidal M, Barábasi AL . Network—based in silico drug efficacy screening. Nat Commun 2016; 7(1):10331.

[52]	Lin L, Yang T, Fang L, Yang J, Yang F, Zhao J . Gene gravity—like algorithm for disease gene prediction based on phenotype—specific network. BMC Syst Biol 2017; 11(1):121.

[53]	Huang Y, Fang J, Lu W, Wang Z, Wang Q, Hou Y, et al. A systems pharmacology approach uncovers wogonoside as an angiogenesis inhibitor of triple—negative breast cancer by targeting Hedgehog signaling. Cell Chem Biol 2019; 26(8):1143—58.e6.

[54]	Shin GR, Kim HE, Ju HJ, Kim JH, Choi S, Choi HS, et al. Injectable click—crosslinked hydrogel containing resveratrol to improve the therapeutic effect in triple negative breast cancer. Mater Today Bio 2022; 16:100386.

[55]	Zheng J, He W, Chen Y, Li L, Liang Q, Dai W, et al. Erianin serves as an NFATc1 inhibitor to prevent breast cancer—induced osteoclastogenesis and bone destruction. J Adv Res 2025; 69:399-411.

[56]	Guo J, Chen T, Ma Z, Qiao C, Yuan F, Guo X, et al. Oridonin inhibits 4T1 tumor growth by suppressing Treg differentiation via TGF—β receptor. Int Immunopharmacol 2020; 88:106831.

[57]	Shi X, Gekas C, Verduzco D, Petiwala S, Jeffries C, Lu C, et al. Building a translational cancer dependency map for the cancer genome atlas. Nat Cancer 2024; 5(8):1176-94.

[58]	Wang Q, Wang J, Yu D, Zhang Q, Hu H, Xu M, et al. Benzosceptrin C induces lysosomal degradation of PD—L1 and promotes antitumor immunity by targeting DHHC3. Cell Rep Med 2024; 5(2):101357.

[59]	Yin Y, Fan Y, Ouyang Q, Song L, Wang X, Li W, et al. Sacituzumab tirumotecan in previously treated metastatic triple—negative breast cancer: a randomized phase 3 trial. Nat Med 2025; 31(6):1969-75.

[60]	Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple—negative breast cancer. J Hematol Oncol 2022; 15(1):121.

[61]	Ding Y, Chen X, Liu C, Ge W, Wang Q, Hao X, et al. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells. J Hematol Oncol 2021; 14(1):19.

[62]	Yao X, Xie R, Cao Y, Tang J, Men Y, Peng H, et al. Simvastatin induced ferroptosis for triple—negative breast cancer therapy. J Nanobiotechnology 2021; 19(1):311.

[63]	Zhang L, Song J, Kong L, Yuan T, Li W, Zhang W, et al. The strategies and techniques of drug discovery from natural products. Pharmacol Ther 2020; 216:107686.

[64]	Zhang J, Cheng X, Chen G, Chen X, Zhao X, Chen W, et al. Discovery of a novel selective PAK1/HDAC6/HDAC10 inhibitor ZMF—25 that induces mitochondrial metabolic breakdown and autophagy—related cell death in triple—negative breast cancer. Research 2025; 8:0670.

[65]	Tan A, Huang H, Zhang P, Li S . Network—based cancer precision medicine: a new emerging paradigm. Cancer Lett 2019; 458:39-45.

[66]	Wang X, Morris—Natschke SL, Lee KH . New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 2007; 27(1):133-48.

[67]	Ip SP, Yang H, Sun HD, Che CT . Dihydroisotanshinone I protects against menadione—induced toxicity in a primary culture of rat hepatocytes. Planta Med 2002; 68(12):1077-81.

[68]	Wu CY, Yang YH, Lin YY, Kuan FC, Lin YS, Lin WY, et al. Anti—cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway. Oncotarget 2017; 8(25):40246-63.

[69]	Lin YY, Lee IY, Huang WS, Lin YS, Kuan FC, Shu LH, et al. Danshen improves survival of patients with colon cancer and dihydroisotanshinone I inhibits the proliferation of colon cancer cells via apoptosis and Skp2 signaling pathway. J Ethnopharmacol 2017; 209:305—16.

[70]	Lin YS, Shen YC, Wu CY, Tsai YY, Yang YH, Lin YY, et al. Danshen improves survival of patients with breast cancer and dihydroisotanshinone I induces ferroptosis and apoptosis of breast cancer cells. Front Pharmacol 2019; 10:1226.

[71]	Sun C, Deng S, Han B, Han X, Yu Y, Li M, et al. Dihydrotanshinone I induces autophagic cell death in ovarian cancer by disrupting the SORT1—mediated autophagy—lysosome pathway. Engineering 2025; 51:280-96.

[72]	Liao Y, Li S, An J, Yu X, Tan X, Gui Y, et al. Ethyl acetate extract of Antenoron filiforme inhibits the proliferation of triple negative breast cancer cells via suppressing Skp2/p21 signaling axis. Phytomedicine 2023; 116:154856.

[73]	Cai Z, Moten A, Peng D, Hsu CC, Pan BS, Manne R, et al. The Skp2 pathway: a critical target for cancer therapy. Semin Cancer Biol 2020; 67(Pt 2):16-33.

[74]	Qin JJ, Yan L, Zhang J, Zhang WD . STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res 2019; 38(1):195.

[75]	García de Herreros A . Dual role of Snail1 as transcriptional repressor and activator. Biochim Biophys Acta Rev Cancer 2024; 1879(1):189037.

[76]	Ma C, Liao R, Chen X, Cao Q, Deng X, Dai Z, et al. RHOA lactylation at oncogenic hotspots promotes oncogenic activity and protein stabilization. Mol Cancer 2025; 24(1):311.

[77]	Xu B, Sun H, Liu S, Liao L, Song X, Wu Y, et al. IFI35 limits antitumor immunity in triple—negative breast cancer via CCL2 secretion. Oncogene 2024; 43(10):693-702.

[78]	Fang W, Kozai Y, Acevedo DS, Brodine R, Gorrepati HS, Arviso N, et al. Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming. Cancer Biol Ther 2025; 26(1):2535824.

[79]	Hu W, Si Y, Wen X, Lin D, Yu Z, Xie X, et al. Pharmacological effects and mechanisms of tanshinone IIA in bone injury repair. Pharmaceuticals 2025; 18(9):1338.

[80]	Hegde M, Girisa S, BharathwajChetty B, Vishwa R, Kunnumakkara AB . Curcumin formulations for better bioavailability: what we learned from clinical trials thus far? ACS Omega 2023; 8(12):10713-46.

[81]

Wang D, Yu W, Cao L, Xu C, Tan G, Zhao Z, et al. Comparative pharmacokinetics and tissue distribution of cryptotanshinone, tanshinone IIA, dihydrotanshinone I, and tanshinone I after oral administration of pure tanshinones and liposoluble extract ofSalvia miltiorrhiza to rats. Biopharm Drug Dispos 2020; 41(1—2):54-63.